Engflag

Cilory

Quick links to important sections

Cilory

There is no image.

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cilory

Quick Facts

Attribute Detail
Active Ingredient Cilnidipine (sometimes in combination with others)
Drug Class Calcium Channel Blocker (CCB)
Primary Use Management of essential hypertension (high blood pressure)

Cilory is a brand name medication primarily used for the treatment of hypertension (high blood pressure). Its main active component is cilnidipine, a dual L-/N-type calcium channel blocker that belongs to the dihydropyridine class of medicines. Hypertension is a chronic condition where the force of the blood against the artery walls is consistently elevated, which can increase the risk of serious cardiovascular events such as heart attacks and strokes.

Cilnidipine works by blocking the entry of calcium into the smooth muscle cells of blood vessel walls. This action causes the blood vessels to relax and widen, a process known as vasodilation. By relaxing the vessels, the resistance to blood flow is reduced, which effectively lowers the overall blood pressure and lessens the workload on the heart.

The medication may be prescribed alone (containing only cilnidipine) or as a combination tablet alongside other antihypertensive agents, such as beta-blockers (like metoprolol) or angiotensin II receptor blockers (like telmisartan) for patients whose blood pressure is not adequately controlled with a single drug.

Regulatory References

  1. High Blood Pressure (Hypertension)

What side effects are possible with Cilory?

Possible Side Effects and Safety Information

The safety profile of Cilory (Cilnidipine) is officially classified by government regulatory documents, detailing expected adverse reactions by frequency and affected system. All safety information provided is derived exclusively from official regulatory labeling.

Documented Adverse Reactions

Adverse reactions are formally categorized by their expected frequency, based on clinical trials and post-marketing surveillance:

  • Common Reactions (may affect up to 1 in 10 people): Reactions frequently documented include peripheral oedema (swelling, typically of the ankles), headache, and dizziness. Other common effects relate to vasodilation, such as flushing and palpitations.

  • System-Organ Classes (SOC): Adverse effects are grouped by affected body systems, including Nervous System Disorders (e.g., drowsiness, tremor), Gastrointestinal Disorders (e.g., nausea, abdominal pain, gingival hypertrophy), and Vascular Disorders.

Serious Adverse Reactions and Safety Constraints

Regulatory documents highlight reactions that are considered serious, often with a frequency classified as unknown:

  • Serious Reactions: The potential for hepatic dysfunction (liver injury) and jaundice, typically accompanied by elevations in liver enzymes, is officially documented. An excessive reduction in blood pressure (severe hypotension) is also noted.

  • Time-Related Pattern: A significant drop in blood pressure is noted to be more likely at the start of treatment (treatment initiation).

  • Population and Conditions: Use is generally not recommended during pregnancy or breastfeeding. Particular caution is required in patients with severe hepatic impairment or severe renal impairment, as these conditions are often listed as contraindications in official labeling. Caution is also advised in patients with certain pre-existing cardiac conditions, such as unstable angina or untreated congestive cardiac failure.

Overdose and Emergency Response

The official regulatory documentation for Cilory (cilnidipine) describes overdosage primarily through profound cardiovascular compromise, consistent with its class as a Calcium Channel Blocker. An overdose may result in an excessive reduction in blood pressure (severe hypotension) and an abnormally slow heartbeat (bradycardia). Other documented clinical signs include confusion, lightheadedness, and an increase in blood sugar levels (hyperglycemia), reflecting systemic disturbances. Overdose scenarios carry the risk of progressing to shock and cardiovascular collapse, which are classified as severe, life-threatening outcomes.

When to Seek Help

Immediate medical attention must be sought when an overdose is suspected, or if the reduction in blood pressure is remarkable, as specified in the official label. Emergency services or poison control must be contacted right away.

Supportive Care and Monitoring

Management is strictly symptomatic and supportive; no specific antidote is known. Official instructions for treating severe hypotension include administering fluid therapy and vasopressors, along with positional support such as lifting the lower extremities. Continuous monitoring of vital signs and the heart’s electrical activity (ECG) is required. Extended hospital observation, potentially for up to 24 hours, is necessary to address the risk of delayed or persistent toxicity.

Therapeutic Uses of Cilory

Cilnidipine is commonly used for managing chronic hypertension, and is considered relevant in contexts involving heightened systemic burden.

This medication is primarily used for the long-term control of essential hypertension, helping to address chronically elevated blood pressure readings. It may contribute to supporting heart and kidney function, generally making it particularly relevant for patients with high blood pressure that coexists with conditions like diabetes mellitus or signs of early kidney strain (such as proteinuria). The drug also plays a role in managing specific patterns of blood pressure linked to nervous system responses, such as exaggerated morning hypertension, and offers supportive symptomatic relief for angina pectoris (chest pain).

“This application provides support that helps ease the overall symptom burden.”

Quick Fact: Symptom Management

Cilory assists with maintaining functional stability by addressing symptom clusters that may become intense or disruptive, such as high systolic and diastolic pressure, sympathetic overactivity, and angina symptoms.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Cilory

Cilory (Cilnidipine) is officially approved for use in adults for the management of essential hypertension. The regulatory profile establishes definitive population boundaries for non-eligibility, categorizing groups who must not use the medicine.

Absolute Contraindications

Use is contraindicated for patients with known hypersensitivity to Cilnidipine or any excipient. Absolute exclusions also apply to patients with specific, high-risk cardiovascular conditions, including untreated congestive cardiac failure, unstable angina pectoris, recent myocardial infarction (within one month), or Left ventricular outflow tract obstruction.

Furthermore, severe organ impairment defines non-eligibility: the medicine is contraindicated in cases of severe hepatic impairment and severe renal impairment (GFR < 30 ml/min).

Restricted and Non-Recommended Groups

Population Group Regulatory Status
Pediatric Population Not recommended; safety and efficacy not established in children/adolescents.
Older Adults (Geriatric) Eligible, but requires special care and close observation due to risk of hypotension.
Pregnancy Contraindicated; should not be administered to pregnant women.
Lactation Not recommended; if administration is indispensable, discontinue lactation.
Hypotension/Poor Cardiac Reserve Use requires caution and monitoring.

These official statements define patient suitability according to regulator-approved labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory interaction profile for Cilory (Cilnidipine) is primarily defined by two major categories: pharmacokinetic exposure modification and additive pharmacodynamic effects.

Contraindicated and Restricted Combinations

Co-administration with strong inhibitors of the CYP3A4 enzyme (such as Azole antifungals like Itraconazole) is officially contraindicated because the inhibition of this metabolic pathway is documented to substantially elevate the plasma concentration of Cilnidipine. Similarly, the food product Grapefruit or Grapefruit Juice is explicitly contraindicated as its consumption is officially stated to increase the blood concentration of this medicine.

Pharmacokinetic and Pharmacodynamic Effects

The co-administration of Cilory with other antihypertensive agents (e.g., ACE inhibitors or beta-blockers) is officially described to lead to an additive or synergistic enhancement of the blood pressure-lowering effect, which may result in an excessive decrease in blood pressure. Conversely, medicines that act as CYP450 inducers, such as Rifampicin, may reduce the effectiveness of Cilnidipine by enhancing its clearance. Caution is also advised regarding the potential for Cilnidipine to reduce the clearance and increase the plasma concentration of Digoxin. Furthermore, regulatory notes caution that patients with severe liver dysfunction may experience an increased risk of drug accumulation and enhanced interaction severity.

Mechanism of Action

Dual Action on Vascular Calcium Channels

Cilory's core action is rooted in the cilnidipine mechanism, which involves the blockade of both L-type and N-type voltage-dependent calcium channels (CaV1 and CaV2.2). By inhibiting the influx of calcium ions into arterial smooth muscle cells, the drug initiates vasodilation (vessel widening), while the unique N-type blockade at nerve endings suppresses the release of Norepinephrine (Noradrenaline). This dual action targets the pathways responsible for vascular tone and sympathetic outflow, resulting in reduced systemic vascular resistance and suppression of sympathetic-driven vascular tone.

Modulation of Adrenergic and Neurohormonal Pathways

In combination formulations, Cilory engages additional mechanisms that modulate systemic regulatory pathways. Components such as metoprolol function through antagonism of beta1-adrenergic receptors (beta1-AR) to directly decrease heart rate and contractility, which decreases cardiac output and subsequent cardiac oxygen demand. Alternatively, agents like telmisartan inhibit the Angiotensin II Type 1 receptor (AT1) to block the vasoconstrictive and volume-retaining signals of the RAAS. This multi-target engagement acts on independent signaling regulators—adrenergic signaling and neurohormonal balance—producing a multifaceted modulation of circulatory system dynamics.

Dosage and Administration Information

How to Use Cilory

Cilory, containing the active substance Cilnidipine, is administered strictly via the oral route as a tablet for the long-term management of essential hypertension. The proper use of this medicine is structured around a consistent daily schedule and specific administration principles.

Official Administration Guidelines

Instruction Detail
Route of administration: Oral
Dosing schedule (Adults): Starting Dose: Typically 5 mg or 10 mg once daily. Maintenance Dose: The usual range is 5 mg to 10 mg once daily. Maximum Dose: Dosage may be increased up to 20 mg once daily.
Timing in relation to meals: Administered after breakfast (with food).
Preparation requirements: The tablet must be swallowed whole with water; it must not be crushed, chewed, or dissolved
Age-group administration rules: Older Adults: Treatment should begin at the lowest dose of 5 mg. Pediatric Patients (<18 years): Safety and efficacy are not established.
Special procedural conditions: Must be taken at the same time each day for consistent blood pressure control. Dose adjustments (titration) should be made gradually, with efficacy assessed over several weeks at each level.

Connection to the Overall Use Protocol

These instructions define a standardized, once-daily regimen for continuous use. The protocol mandates consistent daily timing and maintaining the physical integrity of the tablet to ensure the drug is administered as designed for sustained effect. The need for cautious initiation with the lowest dose for older adults reflects a standard guideline for this population.

Recent Clinical Evidence

Evidence for Use in Essential Hypertension

The core research for Cilory (Cilnidipine) was studied for its use in adults with essential high blood pressure, primarily involving Randomized Controlled Trials (RCTs) and meta-analyses. These studies monitored outcomes related to systemic functional status, focusing on changes in both Systolic and Diastolic Blood Pressure across various settings, including 24-hour monitoring. Trials reported measurements of changes in blood pressure readings that were observed in individuals receiving the medication. However, many detailed comparative studies were observed in specific geographical regions, meaning the results apply only to the populations studied.

Focused Evidence and Research Gaps

Research was evaluated in patients with hypertension and coexisting conditions like Diabetes Mellitus or markers of early kidney status (such as proteinuria). In these subgroups, trials monitored outcomes related to changes in renal function markers. Separate studies also examined the medication’s association with patterns in the Pulse Rate and sympathetic nervous activity, as well as changes in blood markers like serum triglycerides and uric acid levels.

The majority of dedicated comparative trials have limited follow-up durations, often less than one year. Consequently, there is limited information for long-term outcomes regarding the medication's impact on hard cardiovascular events (like major heart events). Data for certain groups, including children, pregnant women, and those with severe hypertension, remain insufficient, and the evidence quality varies across specialized studies.

Key Studies & References

  1. CILNIDIPINE: Philippines Food and Drug Administration (FDA) Product Information Sheet (Regulatory Document)

Frequently Asked Questions (FAQ)

Common questions about Cilory (FAQ)

Q: What are the most common side effects people mention when taking Cilory?

A: According to official regulatory labeling, the most common documented reactions include peripheral oedema (swelling, typically of the ankles), headache, and dizziness. Other common effects relate to vasodilation, such as flushing and palpitations.

Q: Is it true that Cilory can interact with blood pressure medications?

A: Yes, official regulatory labeling describes that co-administration with other antihypertensive agents may lead to an additive or synergistic enhancement of the blood pressure-lowering effect. This means the combination may result in a greater overall decrease in blood pressure.

Q: Can Cilory be used alongside antibiotics?

A: The medicine's interaction profile is partly defined by its metabolism through the CYP3A4 enzyme. Strong inhibitors of this enzyme are contraindicated, and other medicines, including certain antibiotics, that affect this pathway may require caution due to the potential for changes in the concentration of Cilory in the blood.

Q: What kind of monitoring might be needed while taking Cilory?

A: Monitoring is based on the patient's overall health and conditions. For example, older adults may require close observation. Studies have examined the monitoring of renal function markers (related to kidney health) in specific patient subgroups. The potential for liver-related issues (hepatic dysfunction) is also documented in the safety profile.

Q: How is the safety of Cilory monitored by regulatory agencies?

A: The official safety profile is established and continuously tracked by government regulatory documents. This classification is based on data collected from pre-approval clinical trials and ongoing post-marketing surveillance once the drug is available to the public.

Q: Is Cilory used to treat sudden symptoms or long-term conditions?

A: Official guidelines indicate that Cilory is primarily administered for the long-term management of essential hypertension (high blood pressure). It is designed to be taken continuously as part of a daily regimen, not for sudden symptoms.

Q: Is there a generic version of Cilory available?

A: Yes, the active ingredient in Cilory is Cilnidipine, which is the recognized generic name. Cilnidipine is available under various generic and brand names in different regions globally.

Q: Why is it important to know who should not use Cilory?

A: Official regulatory documents define specific contraindications (absolute exclusions) to protect patients from serious risk. These are based on conditions that increase the risk of serious adverse reactions, such as an excessive drop in blood pressure, or conditions that increase the risk of drug accumulation in the body, such as severe liver impairment.

Q: Does the time of day I take Cilory matter?

A: Official administration guidelines recommend that it be taken after breakfast and at the same time each day. This consistent timing is specified to ensure a stable daily regimen and sustained 24-hour blood pressure control.

Q: How quickly does Cilory usually start working?

A: Studies report that the medicine reaches its maximum concentration in the blood within approximately two hours of administration. While the drug starts acting quickly, the overall full antihypertensive effects are generally described as slow in onset and long lasting.

Q: How long does the effect of one dose of Cilory last?

A: According to official product information, when Cilory is taken once daily in subjects with essential hypertension, it is reported to produce an antihypertensive effect lasting for 24 hours.

Q: Can Cilory affect my sleep schedule?

A: Drowsiness, which is a state of feeling sleepy or tired, is listed as a documented common adverse effect of this medication. This feeling of drowsiness could potentially affect a person's sleep-wake cycles.

Q: Does taking Cilory affect long-term health?

A: Official documents note that the majority of dedicated comparative trials have limited follow-up durations. This means that there is limited information for long-term outcomes regarding the medicine's impact on hard cardiovascular events (like major heart attacks or strokes).

Q: Why do some forums say Cilory is used for things not mentioned in the official description?

A: The regulatory documents provided to patients and healthcare professionals only define the medicine's use for its single primary approved indication, which is the management of essential hypertension. Any discussion of unapproved uses is outside of this official scope.

Q: Is it okay to drive while taking Cilory?

A: Official safety advice cautions that the medicine may cause dizziness. Activities requiring mental focus, such as driving or operating machinery, should be undertaken with caution until it is known how the medicine affects an individual.

Q: Can I take vitamins or herbal products while using Cilory?

A: Official documents advise caution regarding interactions, particularly with agents that affect the CYP3A4 enzyme or those that have an additive blood pressure lowering effect. Any product, including vitamins or herbal supplements, that could affect these biological pathways may require caution.

Q: Is Cilory known to affect mood or emotions?

A: While the drug acts on parts of the nervous system, official adverse reaction lists typically categorize documented effects as Nervous System Disorders, such as dizziness and drowsiness. Changes specifically related to mood or emotions are not commonly listed as adverse reactions.

Q: Can I stop taking Cilory suddenly?

A: Regulatory-aligned patient guidance describes that sudden discontinuation may cause blood pressure to increase again. The official information recommends that treatment changes be discussed with a healthcare professional.

Q: What is the typical timeframe for seeing the full benefits of Cilory?

A: Based on clinical study data, the maximum therapeutic effect of the medicine is typically achieved by 4 to 8 weeks of continuous daily dosing.

Q: Does Cilory require a special prescription?

A: As the drug is authorized through formal regulatory pathways for a serious medical condition, it is a prescription-only medicine. It cannot be obtained without a valid prescription from a licensed healthcare provider.

Q: What should I do if the side effects of Cilory bother me?

A: Official non-directive guidance suggests seeking the assessment of a healthcare professional (such as a doctor or pharmacist) if side effects persist, worsen, or cause concern.

How should Cilory be stored and disposed of?

The storage and disposal of Cilory (Cilnidipine) are governed by official regulations to maintain product stability and ensure environmental safety.

Storage & Disposal Scope

Category Official Regulatory Requirement
Labeled storage temperature Store the medicinal product below 30°C.
Light/moisture protection It is mandatory to Protect from light and Protect from moisture.
Packaging-related storage Must be stored in the original container (e.g., blister pack).
Child-protection storage Keep out of the sight and reach of children.

Official Disposal Requirements

Official labeling requires that unused or expired product must be disposed of as waste according to national and local regulations. Environmental restrictions explicitly state that the product must not be thrown away via wastewater or household waste and must not enter sewers or ground water.

This profile defines that the medicine must be stored under controlled conditions to ensure its 3-year shelf life, specifically by limiting temperature below 30°C. Compliance with packaging rules maintains protection from light and moisture. The labeling includes mandatory child-safety constraints and instructions to utilize approved waste management procedures for disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Cilory found in:

A-Z Index: